Autoimmune Association and 50+ Patient Groups Send Letter to Key Members of Congress on Drug Pricing Priorities for Autoimmune Patients

Washington, DC, July 30, 2021 – Autoimmune Association sent a letter to key members of Congress with the undersigned 50+ patient groups on the importance of drug pricing policy concerns, priorities, and solutions for individuals living with autoimmune disease.

At a high-level, the letter focuses on the following concerns;

• Concerns With Foreign-Reference Pricing
• QALY as Discriminatory
• Access Restrictions to Medicines Now, Lack of Future Cures

We also suggest patient-focused policy solutions;

• Counting Copay Assistance Toward Deductible, Out-of-Pocket Caps
• Ensuring Discounts Go Directly to Patient
• Addressing Rebates in the System, Highlighting PBM Practices

Specifically, the letter went to House and Senate leadership, House E&C, Senate HELP, and Senate Finance, and the group of 10 democrats who wrote a letter to Speaker Pelosi regarding concerns for certain drug pricing policies under HR3.

###

About AARDA
Autoimmune Association is the nation’s only nonprofit organization dedicated to bringing a national focus to autoimmunity as a category of disease and a major women’s health issue and promoting a collaborative research effort in order to find better treatments and a cure for all autoimmune diseases.

For upcoming Autoimmune Association events visit Events Calendar at www.aarda.org. For more information, visit www.aarda.org. Follow us on social media: Facebook, Twitter, LinkedIn, Instagram, and YouTube.

Media Contact:
Katie Baumer
[email protected]
202-800-5364